Alexion Tackles Rare Disease Affecting Infants
By Catherine Shaffer
Friday, February 11, 2011
Alexion Pharmaceuticals Inc. will tackle a new category of disease following its acquisition of key technology assets from Germany-based Orphatec Pharmaceuticals GmbH. Alexion will take over development of an investigational therapy for molybdenum cofactor deficiency (MoCD) Type A, a rare disease that causes brain damage and death in infants. The move follows a solid earnings report, featuring Soliris sales of $156 million for the fourth quarter.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.